글로벌 수신증 시장 – 2031년까지의 산업 동향 및 예측

수신증 시장 분석 및 규모

글로벌 수신증 시장은 인지도 향상, 의료 기술 발전, 요로 폐쇄 발생률 증가에 힘입어 성장하고 있습니다. 소변이 쌓여 신장이 붓는 것을 특징으로 하는 수신증은 신장 결석 , 종양 또는 선천적 이상을 포함한 다양한 원인으로 전 세계적으로 상당수의 개인에게 영향을 미칩니다. 시장 확장은 또한 초음파, CT 스캔, MRI와 같은 진단 혁신에 의해 촉진되어 조기 발견 및 치료 계획이 용이해집니다. 또한 요관 스텐트 및 신루술과 같은 외과적 개입이 주요 치료법으로, 증상을 완화하고 신장 기능을 보존합니다.

글로벌 수신증 시장 규모는 2023년에 32억 2천만 달러로 평가되었으며, 2031년까지 67억 2천만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 9.64%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

보고 범위 및 시장 세분화       

Market Definition

Hydronephrosis is a medical condition characterized by the swelling or dilation of one or both kidneys due to a buildup of urine. This occurs when there is an obstruction or blockage in the urinary tract, preventing urine from draining properly from the kidney to the bladder. The obstruction can be caused by various factors, such as kidney stones, congenital abnormalities, tumors, or scarring from previous infections.   

Hydronephrosis Market Dynamics

Drivers

• Increasing Prevalence of Hydronephrosis   

The prevalence of hydronephrosis is steadily increasing globally, primarily due to rising incidences of urinary tract obstructions and various kidney disorders. Factors such as kidney stones, tumors, congenital anomalies, and infections contribute significantly to the development of hydronephrosis. The condition affects individuals of all ages but is particularly prevalent among adults and elderly populations. As lifestyles evolve, dietary habits change, and chronic conditions like diabetes and hypertension become more widespread, the risk factors for urinary tract complications and kidney-related disorders increase, driving the market growth.  

• Growing Geriatric Population Prone to Kidney-Related Disorders  

The global demographic shift towards an aging population has led to a heightened susceptibility to kidney-related disorders, including hydronephrosis. Elderly individuals often experience physiological changes that affect kidney function, such as decreased renal blood flow and diminished ability to concentrate urine. These factors, coupled with the prevalence of chronic diseases like diabetes and hypertension among the elderly, contribute to an increased incidence of hydronephrosis. As the elderly population continues to grow, healthcare providers face greater demands in managing and treating kidney-related conditions effectively, driving the market growth.

Opportunities

• Rising Healthcare Expenditure     

Recent advancements in the treatment of hydronephrosis have revolutionized patient care, offering more effective and less invasive options for management. Minimally invasive surgical procedures, such as ureteral stenting and nephrostomy, have become standard practice in relieving urinary tract obstructions and restoring kidney function. These procedures not only reduce recovery times and hospital stays but also minimize the risk of complications compared to traditional open surgeries. Moreover, pharmaceutical therapies aimed at addressing underlying causes of hydronephrosis, such as medications to dissolve kidney stones or manage infections, have improved patient outcomes significantly, creating opportunities for market growth. 

• Advancements in Treatment Options for Hydronephrosis     

The global rise in healthcare expenditure reflects increasing investments in infrastructure, technology, and patient care, which are pivotal in addressing complex medical conditions like hydronephrosis. Governments and private sectors are allocating substantial resources towards improving healthcare accessibility and quality, particularly in developing regions where infrastructure gaps exist. This surge in funding supports the expansion of healthcare facilities, procurement of advanced medical equipment, and training of healthcare professionals specializing in kidney-related disorders. In addition, higher healthcare spending fosters research and development initiatives aimed at discovering innovative treatments and diagnostic tools for hydronephrosis.  These are creating significant market opportunities, reducing the burden of kidney-related diseases on individuals and societies alike.

Restraints/Challenges

• Adverse Effects of Medications and Surgical Interventions 

While advancements in hydronephrosis treatment offer significant benefits, they also come with potential risks and side effects that patients and healthcare providers must consider. Medications prescribed for managing kidney stones or infections may cause adverse reactions such as gastrointestinal upset or allergic responses in some individuals. Similarly, surgical interventions like ureteral stenting or nephrostomy carry risks of complications such as infection, bleeding, or damage to surrounding tissues. These potential side effects underscore the importance of thorough risk assessment and patient counselling before initiating treatment.  

• Regulatory Requirements for New Medical Devices and Treatments        

Navigating the regulatory landscape presents significant challenges for companies developing new medical devices and treatments for hydronephrosis. Stringent regulatory requirements, varying across different regions and countries, necessitate extensive clinical trials, safety evaluations, and documentation to obtain approvals. These processes aim to ensure the efficacy, safety, and quality of healthcare products before they reach the market and are used in patient care. However, the lengthy approval timelines and resource-intensive nature of regulatory compliance can pose barriers to innovation and market entry for smaller companies or start-ups.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In August 2023, Novartis announced the successful acquisition of Chinook Therapeutics, Inc., a biopharmaceutical company headquartered in Seattle, WA. Chinook Therapeutics specializes in the research, development, and commercialization of precision medicines targeting kidney diseases

Hydronephrosis Market Scope

The market is segmented on the basis of indication, treatment, type, and diagnosis. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Indication

• Intrinsic
  • Acute Unilateral Obstructive Uropathy
  • Kidney Stone
  • Bladder Cancer
  • Bladder Stones
  • Cystocele
  • Urethral Stricture
  • Urethral Cancer
  • Others
• Extrinsic
  • Retroperitoneal Fibrosis
  • Ovarian Vein Syndrome
  • Cancer of the Cervix
  • Cancer of the Prostate
  • Uterine Prolapse
  • Prostate Cancer
  • Pregnancy
  • Others

Treatment

• Shock Wave Lithotripsy
• Laparoscopy
• Bladder Catheterization
• Steroid Therapy
• Others

Type

• Unilateral Hydronephrosis
• Bilateral Hydronephrosis

Diagnosis

• Laboratory Test
  • Urinalysis
  • Complete Blood Count
  • Electrolyte Analysis
  • Others
• Imaging
  • CT Scan Ultrasound
  • Intravenous
  • Pyelography
  • KUB X-Rays
  • Others

Hydronephrosis Market Regional Analysis/Insights

The market is analyzed and market size insights and trends are provided by country, indication, treatment, type, and diagnosis as referenced above.

The countries covered in the market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America.

North America is expected to dominate the market due to increased expenditure on research and development, substantial healthcare spending, a higher prevalence of kidney-related disorders, the presence of key market players, and the introduction of technologically advanced products in these regions.   

아시아 태평양 지역은 의료 분야에 대한 정부 지출 증가, 특히 인도와 중국과 같은 신흥 경제국에서 노령 인구가 증가, 개인 가처분 소득이 증가함에 따라 예측 기간 동안 상당한 성장을 보일 것으로 예상됩니다. 

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 다운스트림 및 업스트림 가치 사슬 분석, 기술 트렌드 및 포터의 5가지 힘 분석, 사례 연구와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 몇 가지 포인터입니다. 또한 글로벌 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세 및 무역 경로의 영향은 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.

의료 인프라 성장 설치 기반 및 신기술 침투

이 시장은 또한 자본 장비에 대한 의료 지출의 모든 국가별 성장, 시장에 대한 다양한 종류의 제품의 설치 기반, 수명선 곡선을 사용한 기술의 영향, 의료 규제 시나리오의 변화 및 시장에 미치는 영향에 대한 자세한 시장 분석을 제공합니다. 이 데이터는 2016-2021년의 과거 기간에 대해 제공됩니다.

경쟁 환경 및 수신증 시장 점유율 분석

시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 애플리케이션 우세입니다. 위에 제공된 데이터 포인트는 시장과 관련된 회사의 초점에만 관련이 있습니다.

시장에서 활동하는 주요 기업은 다음과 같습니다.

• 알러간(아일랜드)
• 암젠 주식회사(미국)
• 사노피(프랑스)
• 노바티스 AG(스위스)
• 파이저 주식회사(미국)
• F. 호프만-라 로슈 유한회사(스위스)
• Teva Pharmaceutical Industries Ltd. (이스라엘)
• 보스턴 사이언티픽 코퍼레이션(미국)
• B. Braun Melsungen AG(독일)
• 스트라이커(미국)
• 짐머 바이오멧(미국)
• 스미스앤네퓨 주식회사(영국)
• 프로메가 코퍼레이션(미국)
• 시그마-알드리치(Sigma-Aldrich) 주식회사(미국)
• Thermo Fisher Scientific Inc. (미국)
• Bio-Rad Laboratories, Inc. (미국)

SKU-13210